AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme ; volume:28 ; number:4 ; day:14 ; month:3 ; year:2011 ; pages:334-340 ; date:4.2011
Advances in therapy ; 28, Heft 4 (14.3.2011), 334-340, 4.2011
- Creator
-
Chinot, O. L.
Motte Rouge, T. de La
Moore, N.
Zeaiter, A.
Das, A.
Phillips, H.
Modrusan, Z.
Cloughesy, T.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-011-0007-3
- URN
-
urn:nbn:de:101:1-2411120911098.472747807081
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chinot, O. L.
- Motte Rouge, T. de La
- Moore, N.
- Zeaiter, A.
- Das, A.
- Phillips, H.
- Modrusan, Z.
- Cloughesy, T.
- SpringerLink (Online service)
Other Objects (12)
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction
Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction
Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction
Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme